Clinical Trials Arena January 2, 2025
According to key opinion leaders, positive SURMOUNT-5 results, alongside Lilly’s business strategy, means Zepbound is set to overtake competitors.
Following positive results from its SURMOUNT-5 trial, Eli Lilly’s Zepbound (tirzepatide) will surpass Novo Nordisk’s Weogvy (semaglutide) in the obesity treatment market, according to a GlobalData analyst.
GlobalData is the parent company of Clinical Trials Arena.
Pointing to the results of Eli Lilly’s recent SURMOUNT-5 trial (NCT05822830), pharma analyst Costanza Alciati commented; “Eli Lilly’s drug is more potent, and perhaps negotiations with national health services will also make it more cost-effective than Wegovy. So, Zepbound is expected to take the lead in the obesity market if it hasn’t already done so.”
Based on SURMOUNT-5 results released last month, Zepbound was more...
Today's Sponsors
Today's Sponsor